Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial
Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irradiation, smaller irradiation fields have been accompanied with an increased risk of out-of-...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 August 2019
|
| In: |
Trials
Year: 2019, Jahrgang: 20, Pages: 1-8 |
| ISSN: | 1468-6694 |
| DOI: | 10.1186/s13063-019-3614-y |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13063-019-3614-y
|
| Verfasserangaben: | Laila König, Martin Dreyling, Jan Dürig, Marianne Engelhard, Karin Hohloch, Andreas Viardot, Mathias Witzens-Harig, Meinhard Kieser, Wolfram Klapper, Christiane Pott, and Klaus Herfarth |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694553868 | ||
| 003 | DE-627 | ||
| 005 | 20220818041126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200415s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-019-3614-y |2 doi | |
| 035 | |a (DE-627)1694553868 | ||
| 035 | |a (DE-599)KXP1694553868 | ||
| 035 | |a (OCoLC)1341315021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a König, Laila |d 1986- |e VerfasserIn |0 (DE-588)1053640579 |0 (DE-627)790403315 |0 (DE-576)409584282 |4 aut | |
| 245 | 1 | 0 | |a Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy) |b a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial |c Laila König, Martin Dreyling, Jan Dürig, Marianne Engelhard, Karin Hohloch, Andreas Viardot, Mathias Witzens-Harig, Meinhard Kieser, Wolfram Klapper, Christiane Pott, and Klaus Herfarth |
| 264 | 1 | |c 30 August 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.04.2020 | ||
| 520 | |a Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irradiation, smaller irradiation fields have been accompanied with an increased risk of out-of-field recurrence. The MIR (MabThera® and Involved field Radiation) trial has shown that the combination of IF-RT at a dose of 30-40 Gy with the anti-CD20 antibody rituximab has led to similar efficacy compared with large field irradiation but with markedly reduced side effects. Immune modulating radiation therapy alone using low-dose radiotherapy (LDRT) of 2 × 2 Gy has been shown to be effective in FL. The GAZAI (GAZyvaro and response Adapted Involved-site Radiotherapy) trial aims to prove the efficacy of LDRT in combination with a novel anti-CD20 therapy. | ||
| 700 | 1 | |a Dreyling, Martin |d 1961- |e VerfasserIn |0 (DE-588)134015819 |0 (DE-627)559478143 |0 (DE-576)300256000 |4 aut | |
| 700 | 1 | |a Dürig, Jan |e VerfasserIn |0 (DE-588)1167428412 |0 (DE-627)103110268X |0 (DE-576)511135750 |4 aut | |
| 700 | 1 | |a Engelhardt-Schagen, Marianne |e VerfasserIn |0 (DE-588)1157252095 |0 (DE-627)1021046116 |0 (DE-576)502797681 |4 aut | |
| 700 | 1 | |a Hohloch, Karin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Viardot, Andreas |d 1968- |e VerfasserIn |0 (DE-588)123546605 |0 (DE-627)082621357 |0 (DE-576)184707498 |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 700 | 1 | |a Kieser, Meinhard |d 1960- |e VerfasserIn |0 (DE-588)103276547X |0 (DE-627)739277766 |0 (DE-576)168963825 |4 aut | |
| 700 | 1 | |a Klapper, Wolfram |d 1971- |e VerfasserIn |0 (DE-588)123029880 |0 (DE-627)082304327 |0 (DE-576)293526842 |4 aut | |
| 700 | 1 | |a Pott, Christiane |e VerfasserIn |0 (DE-588)1020732997 |0 (DE-627)691326142 |0 (DE-576)361909322 |4 aut | |
| 700 | 1 | |a Herfarth, Klaus |e VerfasserIn |0 (DE-588)1032757582 |0 (DE-627)739273116 |0 (DE-576)171352289 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d London : BioMed Central, 2000 |g 20(2019), Artikel-ID 544, Seite 1-8 |h Online-Ressource |w (DE-627)326173552 |w (DE-600)2040523-6 |w (DE-576)107014556 |x 1468-6694 |7 nnas |a Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy) a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial |
| 773 | 1 | 8 | |g volume:20 |g year:2019 |g elocationid:544 |g pages:1-8 |g extent:8 |a Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy) a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13063-019-3614-y |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200415 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1032757582 |a Herfarth, Klaus |m 1032757582:Herfarth, Klaus |d 910000 |d 911400 |e 910000PH1032757582 |e 911400PH1032757582 |k 0/910000/ |k 1/910000/911400/ |p 11 |y j | ||
| 998 | |g 103276547X |a Kieser, Meinhard |m 103276547X:Kieser, Meinhard |d 910000 |d 999701 |e 910000PK103276547X |e 999701PK103276547X |k 0/910000/ |k 1/910000/999701/ |p 8 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |e 910000PW1050736516 |e 910100PW1050736516 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1053640579 |a König, Laila |m 1053640579:König, Laila |d 910000 |d 911400 |e 910000PK1053640579 |e 911400PK1053640579 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1694553868 |e 3623534706 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 15.04.2020"],"recId":"1694553868","name":{"displayForm":["Laila König, Martin Dreyling, Jan Dürig, Marianne Engelhard, Karin Hohloch, Andreas Viardot, Mathias Witzens-Harig, Meinhard Kieser, Wolfram Klapper, Christiane Pott, and Klaus Herfarth"]},"id":{"doi":["10.1186/s13063-019-3614-y"],"eki":["1694553868"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"30 August 2019"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["1468-6694","1745-6215"],"zdb":["2040523-6"],"eki":["326173552"]},"language":["eng"],"origin":[{"publisherPlace":"London","dateIssuedDisp":"2000-","publisher":"BioMed Central","dateIssuedKey":"2000"}],"part":{"pages":"1-8","text":"20(2019), Artikel-ID 544, Seite 1-8","year":"2019","extent":"8","volume":"20"},"title":[{"title":"Trials","title_sort":"Trials"}],"titleAlt":[{"title":"Current controlled trials in cardiovascular medicine"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy) a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trialTrials","note":["Gesehen am 26.09.22"],"pubHistory":["1.2000 -"],"recId":"326173552"}],"title":[{"title":"Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy)","subtitle":"a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial","title_sort":"Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy)"}],"person":[{"family":"König","display":"König, Laila","given":"Laila","role":"aut"},{"display":"Dreyling, Martin","family":"Dreyling","given":"Martin","role":"aut"},{"role":"aut","given":"Jan","display":"Dürig, Jan","family":"Dürig"},{"family":"Engelhardt-Schagen","display":"Engelhardt-Schagen, Marianne","given":"Marianne","role":"aut"},{"role":"aut","given":"Karin","display":"Hohloch, Karin","family":"Hohloch"},{"given":"Andreas","family":"Viardot","display":"Viardot, Andreas","role":"aut"},{"role":"aut","display":"Witzens-Harig, Mathias","family":"Witzens-Harig","given":"Mathias"},{"role":"aut","given":"Meinhard","display":"Kieser, Meinhard","family":"Kieser"},{"role":"aut","given":"Wolfram","family":"Klapper","display":"Klapper, Wolfram"},{"role":"aut","display":"Pott, Christiane","family":"Pott","given":"Christiane"},{"given":"Klaus","display":"Herfarth, Klaus","family":"Herfarth","role":"aut"}],"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a KOENIGLAILTHERAPYOFN3020 | ||